Plott Ronald Todd purchased $17K of PHIO
Plott Ronald Todd purchased 15,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.14 on 2026-08-19.
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHIO
Neutral
low confidence
Mentioned
$PHIO
Relevance
4/10
Decision brief
The 30-second read
01
Why it matters
The transaction is a routine insider purchase with limited market relevance.
02
Market read
Low relevance; small insider buy does not materially affect stock.
03
What to watch
Potential upcoming clinical data not reflected in this filing.
Relevance 4/10Novelty 3/10Timing: post‑market filing on Aug 20
Background
Form 4 filing discloses insider transactions to the SEC.
Company-level read
Ticker impact
Context
Director Plott Ronald Todd purchased 15,000 PHIO shares at $1.14 each, total $17,100.
Expected impact
Minimal impact; unlikely to move price.
Evidence & confidence
Purchase amount is tiny relative to market cap and typical trading volume.
Market effects
Sector
None; biotech sector unchanged.
Regional
None; US market only.
Global
None
Counterpoint
What could challenge this read
Even a small insider purchase could precede a positive catalyst.
Key entities
- CompanyPhio Pharmaceuticals Corp.
Biotech firm developing therapies.
- IndividualPlott Ronald Todd
Director of PHIO.
